If you or a loved one have COVID-19 and meet certain criteria, certain therapies are available to help reduce the severity of the illness.
At Lakeland Regional Health we are committed to your health and well-being and are pleased to be able to offer these therapies to those who qualify.
Monoclonal Antibody Therapy
Monoclonal antibodies are made to fight particular infections after a person is infected. For COVID-19, these antibodies help your body fight the virus and can help to keep you from getting sicker. Monoclonal antibody therapy for COVID-19 has been granted Emergency Use Authorization (EUA) by the Food and Drug Administration (FDA) for patients with COVID-19 who are considered high risk.
The antibodies are given to patients through an intravenous line (a small tube to carry medicines into a vein). This is called an infusion. This treatment may help those who are at high risk of being hospitalized or keep them from getting very sick with COVID-19 according to research.
SOTROVIMAB and BEBTELOVIMAB Monoclonal Antibody Therapy
At Lakeland Regional Health, we offer SOTROVIMAB (manufactured by GlaxoSmithKline) and BEBTELOVIMAB (manufactured by Eli Lilly) to those patients who meet specific criteria based on guidelines in the EUA. The following fact sheets provide more information about these monoclonal antibody therapies:
People ages 12 or older at high risk for developing more serious symptoms of COVID-19 may be eligible for the monoclonal antibody treatments depending on their health history and how long they have had symptoms. To learn about who is high risk for serious COVID-19, you can visit this link: Who is at High Risk for Serious COVID-19? | combatCOVID.hhs.gov
If you think you or your child meet the criteria listed on the HHS website mentioned above, please call 863.284.1654 for more information or to schedule an appointment.
What Can I Expect When I Come for Therapy?
- You will be greeted in the Infusion Center by our experienced and compassionate team
- The product chosen to infuse will be based on supply of agents and efficacy of the product based on prevailing COVID-19 variant circulating in our community.
- Infusion times may vary from 30 seconds to 30 minutes based on the antibody chosen for your treatment. Both products require a one-hour observation period.
- During and after the infusion, you will be continuously monitored by trained healthcare personnel
This product provides pre-exposure, prophylaxis from COVID-19 infection and is designed for populations who are immunocompromised and thought to have a limited response to vaccination OR patients who were unable to complete vaccination due to a severe allergy to a vaccine component.
Talk to your healthcare provider about the Evusheld injection and its risks versus benefits. Your provider will need to provide a prescription for therapy. The subcutaneous injections are administered at the Hollis Cancer Center. There is a one-hour observation period after injection.